ATTR amyloidosis Archives -

Armed with new phase 3 data, AstraZeneca is preparing to file for regulatory approval of eplontersen, an antisense

AZ preps FDA filing for $3.6bn amyloidosis drug eplontersen

https://pharmaphorum.com/news/az-preps-fda-filing-for-3-6bn-amyloidosis-drug-eplontersen/

Market Access/ News/ News/ News/ Sales and Marketing

Alnylam grabs FDA approval for its second amyloidosis therapy

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, ATTR amyloidosis, Ionis Pharmaceuticals, Onpattro, regulatory approval, SOBI, Tegsedi 0 Comment

Four years after getting the first drug approved by the FDA to treat rare disease hereditary ATTR amyloidosis,

Alnylam grabs FDA approval for its second amyloidosis therapy

https://pharmaphorum.com/news/alnylam-grabs-fda-approval-for-its-second-amyloidosis-therapy/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ R&D

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

Phil Taylor Alnylam Pharmaceuticals, AstraZeneca, ATTR amyloidosis, eplontersen, Neurimmune, NI006, Onpattro, Pfizer, Vyndaqel 0 Comment

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline,

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

https://pharmaphorum.com/news/astrazeneca-goes-bigger-in-amyloidosis-with-neurimmune-deal/

News/ News/ R&D

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal

Phil Taylor Alnylam Pharmaceuticals, antisense oligonucleotides, AstraZeneca, ATTR amyloidosis, Ionis Pharmaceuticals, partnering, Pfizer 0 Comment

AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the

AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal

https://pharmaphorum.com/news/az-gets-closer-to-ionis-licensing-amyloidosis-drug-in-3-6bn-deal/

Digital/ News/ News

Alnylam launches digital tool for ATTR amyloidosis patients

Phil Taylor Alnylam, ATTR amyloidosis, digital, digital health, Onpattro 0 Comment

Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to

Alnylam launches digital tool for ATTR amyloidosis patients

https://pharmaphorum.com/news/alnylam-launches-digital-tool-for-aatr-amyloidosis-patients/

News/ News/ R&D

Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal

Phil Taylor ATTR amyloidosis, cardiovascular disease, M&A, Novo Nordisk, partnering, Prothena, rare disease 0 Comment

Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition

Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal

https://pharmaphorum.com/news/novo-nordisk-bulks-up-in-rare-diseases-with-1-2bn-prothena-deal/

News/ News/ R&D

Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug

Phil Taylor ATTR amyloidosis, CRISPR/Cas9, gene editing, Intellia Therapeutics, rare disease, Regeneron 0 Comment

The first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the

Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drug

https://pharmaphorum.com/news/intellia-regeneron-ace-first-trial-with-in-vivo-crispr-drug/

News/ News/ Sales and Marketing/ Top stories

Vyndaqel romps away in US, spurring earnings hike from Pfizer

Phil Taylor ATTR amyloidosis, financial results, Pfizer, tafamidis 0 Comment

Pfizer’s new drug for a rare heart disease – Vyndaqel – has shattered analysts’ sales forecasts in its

Vyndaqel romps away in US, spurring earnings hike from Pfizer

https://pharmaphorum.com/news/vyndaqel-romps-away-in-us-spurring-earnings-hike-from-pfizer/

News/ Rare diseases

Alnylam gears up for first RNAi therapeutic filing in 2017

Andrew McConaghie Alnylam, ATTR amyloidosis, gene silencing, RNAi 0 Comment

US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what

Alnylam gears up for first RNAi therapeutic filing in 2017

https://pharmaphorum.com/news/alnylam-gears-up-for-first-rnai-therapeutic-filing-in-2017/

Trending

ATTR amyloidosis

Login